<DOC>
	<DOCNO>NCT01000506</DOCNO>
	<brief_summary>The purpose study show whether mepolizumab give every 4 week intravenously ( i.v . ) reduce frequency asthma exacerbation subject severe asthma despite receive high dos standard asthma medication . The study look different dos mepolizumab comparison placebo .</brief_summary>
	<brief_title>Dose Ranging Efficacy And Safety With Mepolizumab Severe Asthma</brief_title>
	<detailed_description>A double-blind , placebo-controlled study evaluate efficacy , safety pharmacodynamics three dos ( 75 mg , 250 mg 750 mg ) mepolizumab intravenous ( i.v . ) administer every 4 week compare placebo 52-week treatment period subject severe uncontrolled refractory asthma . Efficacy measure frequency asthma exacerbation . In addition lung function , rescue medication usage , daily symptom , asthma control score , asthma quality life score withdrawal due asthma exacerbation assess . Safety assess adverse event , clinical laboratory evaluation , ECGs , immunogenicity vital sign . Pharmacodynamics assess eosinophil level blood , serum IL-5 eosinophil level induce sputum .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<criteria>Male female Aged 12 65 year inclusive Minimum weight 45kg Clinical feature severe refractory asthma Well document requirement high dose inhale corticosteroid ( ICS ) [ i.e . &gt; = 880mcg/day fluticasone propionate equivalent daily ] least 12 month Using additional controller medication addition high dose ICS least 12 month Persistent airflow obstruction indicate prebronchodilator FEV1 &lt; 80 % predict visit 1 2 peak flow diurnal variability &gt; 20 % 3 day runin Airway inflammation likely eosinophilic nature demonstrate either raise peripheral blood eosinophil ( &gt; =300/microL ) , sputum eosinophil ( &gt; =3 % ) , exhale nitric oxide ( &gt; =50ppb ) prompt deterioration asthma control follow &lt; =25 % reduction regular maintenance dose inhale oral corticosteroid ( OCS ) History 2 exacerbation require systemic corticosteroid previous 12 month Evidence asthma document airway reversibility , airway hyperresponsiveness airflow variability ECG assessment demonstrate QTc &lt; 450msec QTc &lt; 480msec patient bundle branch block Liver function test demonstrate ALT &lt; 2xUpper Limit Normal ( ULN ) , AST &lt; 2xULN , Alk Phos &lt; =1.5xULN , bilirubin &lt; =1.5xULN Female nonchildbearing potential childbearing potential negative pregnancy test screening prepare agree acceptable method contraception Able give write informed consent Able read , comprehend write sufficient level complete study material Current smoker smoke history &gt; =10 pack year Clinically important lung condition asthma Diagnosis malignancy process investigation Unstable liver disease ChurgStrauss syndrome Using methotrexate , troleandomycin , oral gold , cyclosporine , azathioprine experimental antiinflammatory therapy within 3 month screen Omalizumab ( Xolair ) biological treatment inflammatory disease within 6 month Visit 1 Regular use oral systemic corticosteroid disease asthma within 12 month intraarticular , shortacting intramuscular corticosteroid within 1 month intramuscular , longacting depot corticosteroid within 3 month Allergy/intolerance excipients mepolizumab formulation Any investigational drug within 30 day 5 terminal halflives , whichever longer Pregnant breastfeed plan become pregnant Clinically significant disease uncontrolled standard treatment History alcohol misuse substance abuse Parasitic infestation within previous 6 month Known immunodeficiency Unable follow instruction , use electronic diary peak flow meter Known evidence lack adherence controller medication and/or follow physician 's recommendation Previous participation study mepolizumab receive study medication within 90 day</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Dose-ranging</keyword>
	<keyword>Safety</keyword>
	<keyword>Pharmacodynamics</keyword>
	<keyword>eosinophil</keyword>
	<keyword>SB-240563</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Severe refractory asthma</keyword>
	<keyword>mepolizumab</keyword>
	<keyword>Placebo</keyword>
</DOC>